Soluble CD163 impact as a prognostic biomarker in chronic lymphocytic leukemia.

Autor:	Ragab HM; Department of Biochemistry, National Research Centre, Institute of Biotechnology Research, Cairo, Egypt., Attia HRM; Department of Clinical and Chemical Pathology, National Research Centre, Institute of Medical Research and Clinical Studies, Centre of Excellence, Cairo, Egypt., Maksoud NA; Department of Biochemistry, National Research Centre, Institute of Biotechnology Research, Cairo, Egypt., Ibrahim MH; Department of Clinical and Chemical Pathology, National Research Centre, Institute of Medical Research and Clinical Studies, Centre of Excellence, Cairo, Egypt., Mohamed MM; Department of Clinical and Chemical Pathology, National Research Centre, Institute of Medical Research and Clinical Studies, Centre of Excellence, Cairo, Egypt., Kamel A; Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt., Sobeih ME; Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt., Kamal MAM; Department of Clinical Pathology, El Hussein Hospital, Al Azhar University, Cairo, Egypt.5Department of Clinical Pathology, El Hussein Hospital, Al Azhar University, Cairo, Egypt., Abd Elaziz W; Department of Biochemistry, National Research Centre, Institute of Biotechnology Research, Cairo, Egypt.
Jazyk:	angličtina
Zdroj:	The Egyptian journal of immunology [Egypt J Immunol] 2023 Jul; Vol. 30 (3), pp. 74-81.
Abstrakt:	Chronic lymphocytic leukemia (CLL) is a malignant blood disorder in which there is an excess of white blood cells (lymphocytes) in blood and lymphoid tissues. CLL patients experience different clinical behaviors with diversity in disease course and outcome. Accordingly, prognostic markers are crucial for employing appropriate therapy protocols. CD163 (cluster of differentiation 163) is a monocyte/macrophage receptor. Soluble CD163 (sCD163) is an emerging prognostic player in the field of hematopoietic neoplasms. This study aimed to assess the prognostic potential of sCD163 as a serological marker in CLL. The study included 41 CLL patients and 44 apparently normal healthy volunteers as controls. Expression of CD38 and cytoplasmic ZAP 70 in CLL cells was assessed using flow cytometry. Beta 2 microglobulin (B2M), sCD23, and sCD163 serological markers were measured by ELISA. Serum levels of sCD163 were statistically significantly higher in CLL cases compared to controls (p=0.000). sCD163 levels were positively correlated with absolute lymphocyte count, sCD23, and B2M levels (p= 0.027, p=0.01, and p=0.004, respectively). In conclusion, levels of sCD163 in CLL is a promising prognostic tool for evaluating disease progression. (Copyright© by the Egyptian Association of Immunologists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu